Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
13.62
-0.35 (-2.51%)
Mar 6, 2026, 10:53 AM EST - Market open

Janux Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Revenue
1010.598.088.613.64
Upgrade
Revenue Growth (YoY)
-5.55%30.99%-6.14%136.79%-
Upgrade
Cost of Revenue
125.968.3954.9253.4426.24
Upgrade
Gross Profit
-115.9-57.8-46.84-44.83-22.6
Upgrade
Selling, General & Admin
41.7741.0526.1422.2610.33
Upgrade
Operating Expenses
41.7741.0526.1422.2610.33
Upgrade
Operating Income
-157.67-98.85-72.98-67.09-32.93
Upgrade
Interest & Investment Income
44.0429.8514.694.030.26
Upgrade
EBT Excluding Unusual Items
-113.63-68.99-58.29-63.06-32.67
Upgrade
Pretax Income
-113.63-68.99-58.29-63.06-32.67
Upgrade
Net Income
-113.63-68.99-58.29-63.06-32.67
Upgrade
Net Income to Common
-113.63-68.99-58.29-63.06-32.67
Upgrade
Shares Outstanding (Basic)
6254444124
Upgrade
Shares Outstanding (Diluted)
6254444124
Upgrade
Shares Change (YoY)
15.28%22.12%6.14%76.24%2471.20%
Upgrade
EPS (Basic)
-1.83-1.28-1.32-1.52-1.39
Upgrade
EPS (Diluted)
-1.83-1.28-1.32-1.52-1.39
Upgrade
Free Cash Flow
-83.28-44.17-52.43-49.37-18.46
Upgrade
Free Cash Flow Per Share
-1.34-0.82-1.19-1.19-0.78
Upgrade
Operating Margin
-1576.67%-933.58%-902.87%-779.04%-905.39%
Upgrade
Profit Margin
-1136.25%-651.62%-721.18%-732.22%-898.32%
Upgrade
Free Cash Flow Margin
-832.78%-417.20%-648.58%-573.24%-507.51%
Upgrade
EBITDA
-155.64-96.79-71.02-66.25-32.82
Upgrade
D&A For EBITDA
2.032.061.960.840.11
Upgrade
EBIT
-157.67-98.85-72.98-67.09-32.93
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.